Welcome to Coulter Partners Global (English)

18 May 2023

Coulter Partners places Board Director at IN8bio

Coulter Partners is pleased to announce the placement of Jeremy Graff, Ph.D. to the Board of Directors of IN8bio, Inc. (Nasdaq: INAB).

IN8bio is a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies.

Dr. Jeremy Graff spent 17 years at Eli Lilly and Company, where he built and led the translational oncology group, supporting and advancing 31 clinical assets in Eli Lilly’s oncology portfolio. He is a highly respected industry leader in oncology with a track record of success in advancing multiple novel anti-cancer compounds into and through the clinic and has been instrumental in garnering the approval of several oncology products.

Dr. Graff brings a wealth of experience to the board, and as the Chair of IN8bio's Science & Technology Committee, we believe his leadership will be crucial in advancing the development of our novel gamma-delta T cell programs. He brings extensive knowledge of cancer biology, and we welcome him to our team as we continue to witness promising early results and advance toward our mission of achieving Cancer Zero,” said William Ho, CEO and co-founder of IN8bio.

We were pleased to work with Coulter Partners again on this critical project. They continue to deliver top-notch talent with professionalism not seen in most other providers,” he added.

With over two decades of experience in drug development and leadership within the biotechnology and pharmaceutical sectors, Dr. Graff currently serves as the Chief Scientific Officer at IMV Inc, an early-stage Canadian biotechnology company. There, he oversees the company's research programs and the development of its cutting-edge cancer vaccine platform. Previously, Dr. Graff held C-level and senior executive positions at various biotechnology companies. During his nearly 17-year tenure at Eli Lilly and Company, Dr. Graff identified and validated new molecular targets for advanced cancers, working alongside the clinical development team to establish and lead the translational oncology group. This group supported and advanced the 31 clinical assets in Eli Lilly’s oncology portfolio at the time.

Commenting on his appointment, Jeremy Graff, Ph.D., said: “I am honored to be joining IN8bio’s board as I share the company’s commitment to advancing therapies that can make a real impact in the lives of cancer patients with the greatest unmet needs. I look forward to leveraging my drug development expertise to the ongoing progress and the far-reaching potential of IN8bio’s innovative gamma-delta T cell therapies.”

Dr. Graff also serves as a member of the Board of Trustees for the Wood Hudson Cancer Research Laboratory and is on the Scientific Advisory Board of Avicenna Biosciences, Inc. He completed a post-doctoral fellowship at the Johns Hopkins University School of Medicine.

About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC, and genetically modified approaches to develop cell therapies, designed to effectively and specifically identify and eradicate tumor cells.

IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with hematologic malignancies undergoing haploidentical hematopoietic stem cell transplantation. IN8bio is initiating INB-400, a company-sponsored multi -center Phase 2 clinical trial in newly diagnosed glioblastoma, which received IND clearance in late 2022. IN8bio also has a broad portfolio of preclinical programs focused on addressing other hematological and solid tumor cancers.

For more information about IN8bio and its programs, please visit www.IN8bio.com.


A new version of Coulter Partners is available.